Patient1	39 y	Male	24 cycles treatment before CAR-T therapy	DLBCL	CD19-CD22	6.44*10^6/kg	No HBV reactivation
Patient2	60 y	Female	6	DLBCL	CD22	5.85*10^6/kg	No HBV reactivation
Patient3	55 y	Male	12	MM	BCMA	2.64*10^6/kg	No HBV reactivation
Patient4	49 y	Male	6	Aggressive B cell lymphoma	CD19-CD22	10.28*10^6/kg	No HBV reactivation
Patient5	43 y	Female	18	DLBCL	CD19-CD22	5.72*10^6/kg	No HBV reactivation
Patient6	47y	Male	5	B-ALL	CD19	5.6*10^6/kg	No HBV reactivation
Patient7	67 y	Male	7	MM	BCMA	3.49*10^6/kg	No HBV reactivation
Patient8	50 y	Female	9	MM	BCMA	5.59*10^6/kg	No HBV reactivation
Patient9	50 y	Female	6	Lymphoblast lymphoma	CD19-CD22	8.04*10^6/kg	Yes, and recovered after entecavir treatment
Patient10	53 y	Male	6	MM	BCMA	5.1*10^6/kg	Yes, and recovered after entecavir treatment